Search by name:
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Himplasia
Himplasia
Himplasia relieves the symptoms of benign prostatic hyperplasia.
Package
Price
Per Bottles
Savings
Order
30 caps x 1 bottle
$43.99
$43.99
$0.00
30 caps x 2 bottles
$69.99
$35.00
$17.98

Product Description

Common use

Himplasia is an ayurvedic formulation used to improve man's health and relieves the symptoms of benign prostatic hyperplasia. Due to its alpha-adrenoceptor antagonistic and 5-alpha reductase enzyme inhibitory activities this herbal product improves urinary flow rate and reduces post-void residual urine. Himplasia also inhibits proliferation of prostate stroma cells.



Directions

Usual dose of Himplasia is 1-2 tablets taken twice daily with meals. The usage usually continues for three or six months.



Precautions

Use Himplasia with caution if you have hypertension.



Contraindications

Contraindications have not yet been identified.



Missed dose

Take the missed dose as soon as possible. Do not take extra or doubled dose of this herbal product.



Possible side effects

This product is safe for health and has no known side effects.



Storage

Store at room temperature between 59-77 F (15-25 C) away from light and moisture, kids and pets.



Overdose

If you suspect overdose contact your health care advisor as soon as possible.



More information

Gokshura (Tribulus terrestris), Putikaranja (Caesalpinia bonducella), Puga (Areca catechu), Shatavari (Asparagus racemosus), Varuna (Crataeva nurvala), Akika pishti.



Disclaimer

All products presented at this site are not intended to diagnose, treat, cure, or prevent any disease. Don't hesitate to consult your health care practitioner before taking any herbal supplement.

 

FREE SHIPPING
FREE PILLS
10% DISCOUNT
News
2026-10-23
The doctor says she faced a brutal investigation after she passed on complaints brought to her by other ...
2026-10-23
The scientists involved say the results could mark a turning point in cancer treatment, bringing personalised ...
2026-10-22
Concerns raised as big private firms buy up care homes and home help fragmenting in England.
2026-10-22
Current plans for 6% of eligible patients to get Mounjaro by 2028 unambitious, say MPs.